BLOG / 🇺🇸 United States / index intelligence · · daily

S&P 500 Healthcare Sector SEC Filings — October 13, 2026

USA S&P 500 Healthcare

By Gunpowder Editorial ·

7 high priority 3 medium priority 10 total filings analysed

Executive Summary

Across the ten S&P 500 Healthcare filings, the dominant theme is a split between earnings-quality noise and genuine guidance strength.

UnitedHealth and Johnson & Johnson both raised full-year EPS guidance, yet UNH's Q3 operating earnings were flattered by $610 million of favorable prior-period reserve development and J&J's GAAP EPS collapsed to $0.09 on a talc litigation charge, so headline numbers need to be stripped of one-offs before they are trusted. Volume and membership trends are weakening at the managed-care end: UNH revenue slipped to $112.7 billion from $113.2 billion, Optum Health revenue fell 10% YoY, and Medicare Advantage membership shrank by 935,000 since year-end 2025. Capital-structure and governance activity is heavy but largely procedural, including Humana's CenterWell joint venture restructuring that removes a WCAS put option, Medtronic's oversubscribed MiniMed exchange offer with an estimated 18.3% proration, and several board appointments at Zoetis, Merck and Danaher. Insider activity at Intuitive Surgical is limited to routine tax withholding on RSU vestings at $423.96 per share, which signals no material conviction either way. Overall the sector picture is one of guidance held or raised by the largest names, offset by reserve-driven and litigation-driven distortions that will matter for Q4 2026 comparisons.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K · Form 4 · 425

Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from October 05, 2026.

Investment Signals (10)

  • UnitedHealth Group ↓
    ▲

    Raised FY2026 EPS guidance to at least $19.50 (adjusted at least $20.50) and Q3 earnings from operations rose to $6.6B from $4.3B, but $610M of favorable prior-period reserve development flattered MCR and is not run-rate [BEARISH on quality of beat]

  • Johnson & Johnson ↓ (BULLISH)
    ▲

    Raised FY2026 adjusted EPS midpoint to $11.10 and adjusted operational EPS to $11.00, with estimated reported sales midpoint of $101.2B (+7.4%) despite Q3 reported sales up 5.9% YoY to $25.4B

  • Johnson & Johnson ↓ (BEARISH)
    ▲

    STELARA produced an approximate 690 bps drag on Innovative Medicine growth in Q3 2026, and adjusted net earnings fell 6.8% YoY to $6,339M on M&A-related impacts

  • UnitedHealth Group ↓ (BEARISH)
    ▲

    Membership is contracting across all segments since year-end 2025, with Medicare Advantage seniors down 935,000, Employer & Individual down 165,000 and Community & State down 85,000

  • Humana ↓ (BULLISH)
    ▲

    Affirmed FY2026 Adjusted EPS guidance of at least $9.00 while the CenterWell JV restructuring with HPS (BlackRock) removes the WCAS put option, which management expects to significantly reduce balance-sheet liabilities and lower cost of capital

  • Humana ↓ (BEARISH)
    ▲

    GAAP EPS guidance may change due to the liability reduction, and the new BlackRock arrangement creates a fair-value derivative with minimum return protections, adding earnings volatility

  • Intuitive Surgical ↓ (NEUTRAL)
    ▲

    EVP & Chief Legal Officer Gary Loeb had 1,296 shares withheld for taxes (~$549K at $423.96) and retains 6,636 shares after RSU conversion of 2,612 units, a routine vesting pattern with no open-market selling

  • Intuitive Surgical ↓ (NEUTRAL)
    ▲

    SVP & CHRO Patricia Wadors had 1,062 shares withheld (~$450K) and holds 1,078 shares after converting 2,140 RSUs, again consistent with tax-withholding rather than discretionary sales

  • Danaher ↓ (NEUTRAL)
    ▲

    Appointed former CFO Daniel Comas and Dr. Robert Hershberg to the board effective October 9, 2026, expanding it to thirteen; Comas's consulting agreement was terminated September 30 to clear independence, and founders waived 500,000-share RSU grants each

  • Medtronic ↓ (NEUTRAL)
    ▲

    MiniMed exchange offer was oversubscribed with 298.0M shares tendered against 55.0M accepted, implying ~18.3% proration and an exchange of 252.8M MiniMed shares at 4.5939 per Medtronic share; final factor due October 14, 2026

Risk Flags (8)

  • UnitedHealth Group/Reserve Quality↓ [HIGH RISK]
    ▼

    $610M favorable prior-period reserve development inflated Q3 MCR; underlying run-rate medical cost trend is therefore weaker than reported EPS suggests

  • UnitedHealth Group/Membership Decline↓ [HIGH RISK]
    ▼

    Total membership down across Employer & Individual (-165K), Community & State (-85K) and Medicare Advantage (-935K) since year-end 2025, signaling share loss and pressure on premium growth

  • UnitedHealth Group/Optum Health↓ [HIGH RISK]
    ▼

    Revenue fell 10% YoY as value-based care patients were exited in markets lacking clinician capacity, a deliberate contraction that reduces near-term top-line visibility

  • Johnson & Johnson/Litigation↓ [HIGH RISK]
    ▼

    Q3 GAAP net earnings fell 95.9% to $210M (EPS $0.09 vs $2.12 prior year) on a special charge for the proposed ovarian talc resolution; cash and reserve implications remain open

  • Johnson & Johnson/Franchise Erosion↓ [MEDIUM RISK]
    ▼

    STELARA biosimilar pressure drove a ~690 bps drag on Innovative Medicine growth, and the drag is likely to persist into 2027 comparisons

  • Humana/GAAP Guidance↓ [MEDIUM RISK]
    ▼

    Management explicitly warned GAAP EPS guidance may change due to the WCAS liability reduction and the BlackRock derivative accounting, and Q3 2026 financial close is still in progress

  • Medtronic/Exchange Execution↓ [MEDIUM RISK]
    ▼

    Offer was heavily oversubscribed (~5.4x accepted shares tendered), and guaranteed-delivery tenders could still shift the proration factor, leaving the final exchange size uncertain

  • Humana/Deferred Liquidity↓ [LOW RISK]
    ▼

    BlackRock may elect to exit via sale after 2033 with CenterWell holding a right of first offer, so clinic ownership and cash flows beyond 2028 remain contingent on negotiated purchases

Opportunities (7)

  • Johnson & Johnson/Guidance Momentum↓ (OPPORTUNITY)
    ◆

    Upward revisions to adjusted operational EPS ($11.00) and adjusted EPS ($11.10) midpoints on +7.4% reported sales growth suggest the core portfolio is absorbing STELARA erosion and M&A dilution better than feared

  • Johnson & Johnson/Talc Overhang Removal↓ (OPPORTUNITY)
    ◆

    With the ovarian talc resolution now proposed and charged in Q3, the resolution of a long-running liability could re-rate the stock once the settlement is finalized

  • Humana/Capital Structure Reset↓ (OPPORTUNITY)
    ◆

    Removing the WCAS put option and shifting CenterWell clinics to a BlackRock-funded JV should lower the cost of capital and balance-sheet liabilities, a potential re-rating catalyst if Adjusted EPS of at least $9.00 holds

  • Humana/CenterWell Optionality↓ (OPPORTUNITY)
    ◆

    CenterWell may begin purchasing clinics from the JV at its election starting in 2028, giving the company a call option on clinic economics at a pre-agreed structure

  • UnitedHealth Group/Earnings Power Reset↓ (OPPORTUNITY)
    ◆

    Operating earnings rose to $6.6B from $4.3B YoY, and a raised EPS floor of $19.50 implies earnings power is recovering even as membership contracts, rewarding margin discipline over volume

  • Medtronic/Arbitrage Resolution↓ (OPPORTUNITY)
    ◆

    The October 14 final proration announcement will crystallize the MiniMed exchange economics and clear the path for Medtronic to exit or restructure its remaining stake of 252.8M MiniMed shares

  • Intuitive Surgical/Insider Alignment↓ (OPPORTUNITY)
    ◆

    Consistent RSU vesting and tax-withholding across the General Counsel and CHRO, with retained holdings after conversion, reflects long-term ownership rather than distribution pressure

Sector Themes (6)

  • Earnings Quality Divergence in Managed Care
    ◆

    UnitedHealth's raised guidance rests on $610M of reserve releases and a 10% Optum Health revenue decline, while Humana held guidance without changing its operating story; investors should adjust headline EPS for reserve movements when comparing managed-care peers [implication: prefer cash-earnings and MCR-ex-development metrics]

  • Membership Contraction in Medicare Advantage and Commercial
    ◆

    UnitedHealth's Medicare Advantage base fell by 935,000 year-to-date while Humana's CenterWell model is being restructured, pointing to a sector-wide repricing of seniors' benefits and selective market exits [implication: membership growth is now a differentiator rather than a given]

  • Litigation and Patent Cliffs in Large-Cap Pharma
    ◆

    J&J's ~$210M GAAP quarter reflects a talc resolution charge while STELARA caused a ~690 bps growth drag, showing that mature-product erosion and legacy liabilities are concurrently weighing on large-cap pharma [implication: pipeline and litigation certainty are the key diligence items]

  • Capital Structure Re-engineering via Joint Ventures
    ◆

    Humana's CenterWell/HPS arrangement, Medtronic's MiniMed exchange, and the embedded fair-value derivative in the BlackRock deal all show healthcare issuers using off-balance-sheet and exchange structures to lower cost of capital; accounting volatility will rise as a result [implication: expect GAAP-to-adjusted gaps to widen]

  • Governance Refresh Continues at Large-Cap Healthcare
    ◆

    Board appointments at Zoetis (Knobloch, effective Dec 1, board to 13), Merck (Diaz, effective Nov 1, board to 14) and Danaher (Comas and Hershberg, board to 13, with Spoon retiring in 2027) reflect ongoing director renewal and CFO-to-board transitions [implication: independence and skill-matrix changes are frequent but low-impact on near-term fundamentals]

  • Routine Insider Tax-Withholding Dominates RSU Activity
    ◆

    Both Intuitive Surgical insiders' transactions were RSU conversions with share withholding at $423.96, with no open-market sales in the period, indicating neutral sentiment from executive insiders and a steady vesting cadence [implication: insider signal is uninformative until open-market activity appears]

Watch List (8)

Filing Analyses (10)
UNITEDHEALTH GROUP INC 8-K mixed materiality 9/10

13-10-2026

UnitedHealth Group reported Q3 2026 revenues of $112.7 Billion, down from $113.2 Billion a year earlier, while earnings from operations rose to $6.6 Billion from $4.3 Billion and EPS was $4.56 ($4.69 adjusted). The company raised full-year 2026 EPS guidance to at least $19.50 (adjusted at least $20.50), but UnitedHealthcare membership and Optum Health revenue declined year over year, and Q3 MCR benefited from $610 Million of favorable prior-period reserve development.

  • · Net medical reserve development of $610 million favorably impacted the Q3 2026 MCR and is not indicative of run-rate performance.
  • · Optum Health revenue fell 10% YoY as value-based care patients were exited in markets lacking sufficient clinician presence.
  • · UnitedHealthcare membership is shrinking across segments: Employer & Individual down 165,000, Community & State down 85,000, and Medicare Advantage seniors down 935,000 since year-end 2025.
  • · Optum Rx adjusted scripts fell from 414 million to 393 million YoY due to membership declines.
  • · Debt-to-capital ratio rose to 41.7% from 41.2% in Q2 2026, versus a target of approximately 40.0% by year-end.
  • · Medicare & Retirement revenues declined 2.3% YoY due to membership and product mix changes.
  • · Full-year guidance was raised to at least $19.50 EPS (adjusted at least $20.50), reflecting experience through Q3 2026.
HUMANA INC 8-K mixed materiality 7/10

13-10-2026

Humana entered a new joint venture with funds managed by HPS Investment Partners (a BlackRock subsidiary) to operate its CenterWell Senior Primary Care clinics, replacing existing WCAS joint ventures and removing the WCAS put option, which the company expects to significantly reduce associated balance sheet liabilities and lower its cost of capital. Humana affirmed FY 2026 Adjusted EPS guidance of at least $9.00, but flagged that GAAP EPS guidance may change due to the liability reduction and other strategic initiatives, and that Q3 2026 financial close is still in progress.

  • · CenterWell may begin purchasing clinics from the joint venture at its election starting in 2028
  • · If CenterWell has not acquired all clinics by end of 2033, BlackRock may elect to exit via sale process, subject to CenterWell's right of first offer
  • · The new arrangement includes no BlackRock put option and minimum return protections for BlackRock, which create a derivative instrument recorded at fair value on the balance sheet
  • · Guidance was previously issued July 29, 2026 and affirmed in 8-Ks filed September 1, 2026 and October 9, 2026
  • · Company cannot yet reconcile FY 2026 Adjusted EPS guidance to GAAP diluted EPS without unreasonable effort because Q3 2026 close is incomplete
Zoetis Inc. 8-K neutral materiality 3/10

13-10-2026

Zoetis appointed Iris Knobloch to its Board of Directors, effective December 1, 2026, expanding the board from 12 to 13 members. Knobloch currently serves as President of the Festival de Cannes and as Chair of the Deezer S.A. board, and is a director of Lazard, Inc. and Vail Resorts, Inc. The announcement is a governance update with no financial results, guidance, or performance metrics disclosed.

  • · Knobloch is the first woman to serve as President of the Festival de Cannes (since July 2022).
  • · She has chaired the Deezer board since January 2023 and has sat on Lazard's board since April 2018 and Vail Resorts' board since February 2024.
  • · Her prior boards include Accor, LVMH, Central European Media Enterprises and Axel Springer.
  • · She holds a Doctorate in Law from Ludwig-Maximilians-Universitaet and a Master of Laws from New York University.
Medtronic plc SC TO-I/A neutral materiality 7/10

13-10-2026

Medtronic plc filed Amendment No. 3 to its Schedule TO on October 13, 2026, reporting preliminary results of its issuer exchange offer for shares of MiniMed Group, Inc. The offer expired October 9, 2026 and was oversubscribed, with 298,024,452 Medtronic Ordinary Shares validly tendered against 55,032,401 shares Medtronic intends to accept, implying an estimated preliminary proration factor of approximately 18.3% for shares subject to proration. Medtronic will exchange 55,032,401 of its ordinary shares for 252,813,348 MiniMed common shares, subject to a final proration factor pending the guaranteed delivery period.

  • · Exchange offer expired at 12:00 midnight New York City time on October 9, 2026
  • · Proration applies because the offer was oversubscribed; odd-lot holders who tendered all shares were not prorated
  • · Estimated preliminary proration factor is subject to change based on guaranteed delivery tenders, with the final factor expected promptly after the guaranteed delivery period ends
  • · Unaccepted Medtronic shares will be returned in book-entry form after the final proration factor is determined
  • · Registration on Form S-4 (No. 333-298914) was filed by MiniMed to register the MiniMed shares offered
  • · Press release announcing preliminary results issued October 12, 2026 (Exhibit (a)(4)(xxxiv))
JOHNSON & JOHNSON 8-K mixed materiality 9/10

13-10-2026

Johnson & Johnson reported Q3 2026 reported sales of $25,399 Million, up 5.9% YoY, with operational growth of 6.0% and adjusted operational growth of 6.1%. GAAP net earnings fell 95.9% to $210 Million (EPS $0.09) due to a one-time special charge for the proposed talc litigation resolution, while adjusted EPS declined 7.5% to $2.59 and adjusted net earnings fell 6.8% to $6,339 Million, both reflecting M&A-related impacts. Management raised full-year 2026 adjusted operational EPS guidance midpoint to $11.00 and adjusted EPS guidance midpoint to $11.10, while estimated reported sales guidance midpoint is $101.2 Billion (+7.4%).

  • · STELARA caused an approximate 690 basis point drag on Innovative Medicine growth in Q3 2026
  • · Q3 2026 included a one-time special charge for the proposed ovarian talc litigation resolution, the primary driver of the GAAP earnings decline
  • · Q3 2026 Q3 EPS of $0.09 versus $2.12 in Q3 2025 on a GAAP basis
  • · Q3 2026 MedTech growth of 2.5% was modest, supported by electrophysiology, Shockwave, contact lenses, and trauma
  • · Management targets double-digit growth by the end of the decade
  • · Regulatory milestones include FDA approval of IMAAVY for warm autoimmune hemolytic anemia, FDA market authorization of OTTAVA, and FDA Priority Review for RYBREVANT FASPRO in head and neck cancer
  • · Jennifer Taubert is retiring and Tom Cavanaugh will become EVP, Worldwide Chairman Innovative Medicine effective September
Merck & Co., Inc. 8-K neutral materiality 3/10

13-10-2026

Merck & Co. announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Board of Directors effective November 1, 2026, bringing the board to 14 members. He will stand for shareholder election in May 2027. The filing is a board appointment press release with no financial results, guidance, or quantitative performance disclosure.

  • · Diaz previously served as president and CEO of Myriad Genetics and as president and CEO of Kindred Healthcare
  • · Diaz currently sits on the Board of Centene Corporation and the Board of Trustees of Johns Hopkins Medicine
  • · Diaz holds a bachelor's degree in finance and accounting from American University and a J.D. from Georgetown University
INTUITIVE SURGICAL INC 4 neutral materiality 6/10

13-10-2026

EVP & Chief Legal and Complian LOEB GARY had withheld for taxes 1,296 Common Stock at $423.96 (~$549K). LOEB GARY holds 6,636 shares after the transaction.

  • · EVP & Chief Legal and Complian LOEB GARY exercised/converted 2,612 Common Stock
  • · EVP & Chief Legal and Complian LOEB GARY had withheld for taxes 1,296 Common Stock at $423.96 (~$549K)
  • · EVP & Chief Legal and Complian LOEB GARY exercised/converted 2,612 Restricted Stock Units
INTUITIVE SURGICAL INC 4 neutral materiality 5/10

13-10-2026

SVP Chief Human Resources Offi WADORS PATRICIA L had withheld for taxes 1,062 Common Stock at $423.96 (~$450K). WADORS PATRICIA L holds 1,078 shares after the transaction.

  • · SVP Chief Human Resources Offi WADORS PATRICIA L exercised/converted 2,140 Common Stock
  • · SVP Chief Human Resources Offi WADORS PATRICIA L had withheld for taxes 1,062 Common Stock at $423.96 (~$450K)
  • · SVP Chief Human Resources Offi WADORS PATRICIA L exercised/converted 2,140 Restricted Stock Units - 10-10-2024
Medtronic plc 425 neutral materiality 6/10

13-10-2026

Medtronic plc announced preliminary results of its exchange offer for MiniMed Group, Inc. (MMED) shares, which was oversubscribed with 298,024,452 Medtronic ordinary shares validly tendered against 55,032,401 intended for acceptance. Medtronic will exchange all of its remaining MiniMed stake of 252,813,348 shares at 4.5939 MiniMed shares per Medtronic ordinary share, with an estimated proration factor of approximately 18.3%, subject to change pending guaranteed-delivery shares and a final announcement on October 14, 2026. The filing is primarily a preliminary procedural update and does not disclose financial performance metrics.

  • · The exchange offer expired at 12:00 midnight New York time on October 9, 2026.
  • · Odd-lot shareholders tendering all shares were not subject to proration.
  • · Tendered but unaccepted Medtronic shares will be returned in book-entry form after the final proration factor is announced.
  • · Medtronic will retain none of the outstanding MiniMed common stock after completion.
  • · Final proration factor expected October 14, 2026.
DANAHER CORP /DE/ 8-K neutral materiality 4/10

13-10-2026

Danaher appointed Daniel L. Comas (former CFO and EVP, age 62) and Dr. Robert M. Hershberg (age 63) to its Board of Directors effective October 9, 2026, expanding the Board to thirteen members. Director Alan G. Spoon announced his retirement effective at the 2027 annual meeting, and the company's founders, Steven and Mitchell Rales, waived 500,000-share RSU grants each for no consideration.

  • · Comas's consulting agreement with the company (entered April 2024) was mutually terminated effective September 30, 2026, in connection with his board appointment
  • · Spoon's retirement is not due to any disagreement with the company on operations, policies, practices, or committee matters
  • · The founders' RSU waivers were for no consideration
  • · Director compensation for Comas and Hershberg will be prorated, with equity awards prorated through May 15, 2027
  • · Both new directors entered indemnification agreements referenced to Exhibit 10.30 of the FY2025 10-K

Get daily alerts with 10 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 10 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: S&P 500 Healthcare Sector SEC Filings

October 02, 2026

S&P 500 Healthcare Sector SEC Filings — October 02, 2026

October 01, 2026

S&P 500 Healthcare Sector SEC Filings — October 01, 2026

September 30, 2026

S&P 500 Healthcare Sector SEC Filings — September 30, 2026

September 28, 2026

S&P 500 Healthcare Sector SEC Filings — September 28, 2026

🇺🇸 More from United States

View all →

October 06, 2026

US Pre-Market SEC Filings Roundup — October 06, 2026

US Pre-Market SEC Filings Roundup

October 06, 2026

US Merger & Acquisition SEC Filings — October 06, 2026

US Merger & Acquisition SEC Filings

October 06, 2026

USA Insider Trading Pulse — October 06, 2026

USA Insider Trading Pulse

October 06, 2026

US Corporate Board Director Changes SEC Filings — October 06, 2026

US Corporate Board Director Changes SEC Filings
← All United States digests